Newsfeeds - Spark Newswire

1 minute read

FDA Requests For Additional Monitoring For Travere Therapeutics’ Sparsentan In Rare Kidney Disease

Today, 11:23 AM

Following late-cycle review interactions with the FDA, Travere Therapeutics Inc (NASDAQ:TVTX) expects the previously assigned Prescription Drug User Fee Act…

TVTX

3 minute read

Recap Of Monday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 11:23 AM

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…

BLTE

2 minute read

Travere Therapeutics And CSL Vifor Announce EMA Has Accepted For Review The Conditional Marketing Authorization Application For Sparsentan For The Treatment Of IgA Nephropathy

By Benzinga Newsdesk

Today, 11:23 AM

Travere Therapeutics, Inc. (NASDAQ:TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare

TVTX

2 minute read

Earnings

Travere Therapeutics Return On Capital Employed Overview

By Benzinga Insights

Today, 11:23 AM

TVTX

1 minute read

SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $45

By Benzinga Newsdesk

Today, 11:23 AM

SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $42 to $45.

TVTX

1 minute read

FDA Says Travere’s Sparsentan Data Not Sufficient For Accelerated Approval In One Indication

By Vandana Singh

Today, 11:23 AM

Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.

TVTX

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

By Benzinga Insights

Today, 11:23 AM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 11:23 AM

Gainers

BCLI

1 minute read

FDA
News

Travere Therapeutics Provides Regulatory Updates On Its Development Programs

By Benzinga Newsdesk

Today, 11:23 AM

PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase 3 DUPLEX

TVTX

2 minute read

Analyst Ratings

4 Analysts Have This to Say About Travere Therapeutics

By Benzinga Insights

Today, 11:23 AM

Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

TVTX